Logo image of XLRN

Acceleron Pharma (XLRN) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:XLRN -

178.75
-0.93 (-0.52%)
Last: 11/19/2021, 8:33:57 PM
179.92
+1.17 (+0.65%)
After Hours: 11/19/2021, 8:33:57 PM
Buy % Consensus

73

ChartMill assigns a Buy % Consensus number of 73% to XLRN. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 182.68. This target is 2.2% above the current price.
XLRN was analyzed by 17 analysts. The buy percentage consensus is at 73. So analysts seem to be have mildly positive about XLRN.
In the last month the buy percentage fell by 5 points. So the trust of analysts is decreasing.
XLRN was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

XLRN Historical Analyst RatingsXLRN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -43 -39 -35 -31 -27 -23 -19 -15 -11 -7 -3 5 10 15 20

Price Target & Forecast

Price Low Median Mean High 178.75172.71183.60182.68189.00 - -3.38% 2.71% 2.20% 5.73%

Related screens

XLRN Current Analyst RatingXLRN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8
Up and Down Grades
Date Firm Action Rating
2021-10-07 Jefferies Initiate Hold
2021-10-04 Raymond James Downgrade Strong Buy -> Market Perform
2021-10-01 Barclays Downgrade Overweight -> Equal-Weight
2021-10-01 Cowen & Co. Downgrade Outperform -> Market Perform
2021-10-01 Morgan Stanley Downgrade Overweight -> Equal-Weight
2021-09-30 SVB Leerink Maintains Market Perform
2021-09-30 Piper Sandler Downgrade Overweight -> Neutral
2021-09-30 HC Wainwright & Co. Downgrade Buy -> Neutral
2021-09-27 RBC Capital Maintains Sector Perform
2021-03-23 SVB Leerink Downgrade Outperform -> Market Perform
2021-03-12 Wolfe Research Initiate Outperform
2021-03-01 Citigroup Maintains Buy
2021-02-26 SVB Leerink Maintains Outperform
2021-02-26 Morgan Stanley Maintains Overweight
2021-02-26 Piper Sandler Maintains Overweight

Acceleron Pharma / XLRN FAQ

What is the price target for XLRN stock?

17 analysts have analysed XLRN and the average price target is 182.68 null. This implies a price increase of 2.2% is expected in the next year compared to the current price of 178.75.


How do analysts rate Acceleron Pharma (XLRN)?

The consensus rating for Acceleron Pharma (XLRN) is 72.9412 / 100 . This indicates that analysts generally have a positive outlook on the stock.